hct8  (ATCC)

Journal: Frontiers in Oncology

Article Title: Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

doi: 10.3389/fonc.2026.1721685

Figure Lengend Snippet: In vitro evaluation of sequential dosing of SN38 and/or eltanexor in CRC cell lines (HCT8, HCT116, LS1034, and HCT15). (A) Dosing strategies for in vitro viability assay. Cells were incubated with SN38 [10 nM] for the first 24 hours. Cells were then washed with PBS and incubated with eltanexor [100 nM] for an additional 48 hours. (B) Cell viability % measured by CellTiter Glo 2.0 and (C) heatmaps of the 4 CRC cell lines treated sequentially with SN38 [0 - 30 nM] followed by eltanexor [0 -100 μM]. Bliss synergy score was analyzed using SynergyFinder.

Article Snippet: Human CRC cell lines HCT8 (RRID: CVCL_2478), HCT15 (RRID: CVCL_0292), HCT116 (RRID: CVCL_0291), and LS1034 (RRID: CVCL_1382) were purchased from American Type Culture Collection (ATCC) (Manassas, VA; ).

Techniques: In Vitro, Viability Assay, Incubation

Journal: Frontiers in Oncology

Article Title: Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

doi: 10.3389/fonc.2026.1721685

Figure Lengend Snippet: (A) A Western blot analysis of RAD51, p53, p-H2A.X and MSH2 in CRC cell lines HCT8, HCT116, LS1034, and HCT15 following sequential treatment of SN38 and/or eltanexor. (B) Densitometry analysis total cell protein. Cells were exposed to SN38 (10 nM) or vehicle for 6hr. (C) Cells were then washed with PBS and incubated with or without the presence of eltanexor (1 uM) for an additional 24 hr. Nuclear/Cytoplasmic. (D) Densitometry analysis of nuclear/cytoplasmic proteins.

Article Snippet: Human CRC cell lines HCT8 (RRID: CVCL_2478), HCT15 (RRID: CVCL_0292), HCT116 (RRID: CVCL_0291), and LS1034 (RRID: CVCL_1382) were purchased from American Type Culture Collection (ATCC) (Manassas, VA; ).

Techniques: Western Blot, Incubation

Journal: Frontiers in Oncology

Article Title: Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

doi: 10.3389/fonc.2026.1721685

Figure Lengend Snippet: Immunocytochemistry in HCT8 and HCT 116 cell lines. Cells were first treated with SN38 (10 nM) in time series (0 hr, 2 hr, 4 hr, and 6 hr). Cells were washed with PBS and then treated with eltanexor (1 uM) for 48 hours. Cells were fixed and then stained with p53 and p21 for cell cycle arrest or stained with P-H2A.X for double stained DNA breaks. (A) Schematic illustration of dosing strategy, (B) immunostaining in HCT8 cell line and (C) immunostaining in HCT116 cell line.

Article Snippet: Human CRC cell lines HCT8 (RRID: CVCL_2478), HCT15 (RRID: CVCL_0292), HCT116 (RRID: CVCL_0291), and LS1034 (RRID: CVCL_1382) were purchased from American Type Culture Collection (ATCC) (Manassas, VA; ).

Techniques: Immunocytochemistry, Staining, Immunostaining